Find the papers that actually matter

Deep learning-based automated diagnosis of lung cancer has emerged as a crucial advancement that enables healthcare professionals to detect and initiate treatment earlier. However, these models require extensive training datasets with diverse case-specific properties. High-quality annotated data is particularly challenging to obtain, especially for cases with subtle pulmonary nodules that are difficult to detect even for experienced radiologists. This scarcity of well-labeled datasets can limit model performance and generalization across different patient populations. Digitally reconstructed radiographs (DRR) using CT-Scan to generate synthetic frontal chest X-rays with artificially inserted lung nodules offers one potential solution. However, this approach suffers from significant image quality degradation, particularly in the form of blurred anatomical features and loss of fine lung field structures. To overcome this, we introduce DiffusionXRay, a novel image restoration pipeline for Chest X-ray images that synergistically leverages denoising diffusion probabilistic models (DDPMs) and generative adversarial networks (GANs). DiffusionXRay incorporates a unique two-stage training process: First, we investigate two independent approaches, DDPM-LQ and GAN-based MUNIT-LQ, to generate low-quality CXRs, addressing the challenge of training data scarcity, posing this as a style transfer problem. Subsequently, we train a DDPM-based model on paired low-quality and high-quality images, enabling it to learn the nuances of X-ray image restoration. Our method demonstrates promising results in enhancing image clarity, contrast, and overall diagnostic value of chest X-rays while preserving subtle yet clinically significant artifacts, validated by both quantitative metrics and expert radiological assessment.

Early detection of lung cancer in chest radiographs (CXRs) is crucial for improving patient outcomes, yet nodule detection remains challenging due to their subtle appearance and variability in radiological characteristics like size, texture, and boundary. For robust analysis, this diversity must be well represented in training datasets for deep learning based Computer-Assisted Diagnosis (CAD) systems. However, assembling such datasets is costly and often impractical, motivating the need for realistic synthetic data generation. Existing methods lack fine-grained control over synthetic nodule generation, limiting their utility in addressing data scarcity. This paper proposes a novel diffusion-based framework with low-rank adaptation (LoRA) adapters for characteristic controlled nodule synthesis on CXRs. We begin by addressing size and shape control through nodule mask conditioned training of the base diffusion model. To achieve individual characteristic control, we train separate LoRA modules, each dedicated to a specific radiological feature. However, since nodules rarely exhibit isolated characteristics, effective multi-characteristic control requires a balanced integration of features. We address this by leveraging the dynamic composability of LoRAs and revisiting existing merging strategies. Building on this, we identify two key issues, overlapping attention regions and non-orthogonal parameter spaces. To overcome these limitations, we introduce a novel orthogonality loss term during LoRA composition training. Extensive experiments on both in-house and public datasets demonstrate improved downstream nodule detection. Radiologist evaluations confirm the fine-grained controllability of our generated nodules, and across multiple quantitative metrics, our method surpasses existing nodule generation approaches for CXRs.

Reliable deployment of Vision-Language Models (VLMs) in radiology requires validation metrics that go beyond surface-level text similarity to ensure clinical fidelity and demographic fairness. This paper investigates a critical blind spot in current model evaluation: the use of decoding strategies that lead to high aggregate token-overlap scores despite succumbing to template collapse, in which models generate only repetitive, safe generic text and omit clinical terminology. Unaddressed, this blind spot can lead to metric gaming, where models that perform well on benchmarks prove clinically uninformative. Instead, we advocate for lexical diversity measures to check model generations for clinical specificity. We introduce Clinical Association Displacement (CAD), a vocabulary-level framework that quantifies shifts in demographic-based word associations in generated reports. Weighted Association Erasure (WAE) aggregates these shifts to measure the clinical signal loss across demographic groups. We show that deterministic decoding produces high levels of semantic erasure, while stochastic sampling generates diverse outputs but risks introducing new bias, motivating a fundamental rethink of how "optimal" reporting is defined.

Accurate classification of pediatric central nervous system tumors remains challenging due to histological complexity and limited training data. While pathology foundation models have advanced whole-slide image (WSI) analysis, they often fail to leverage the rich, complementary information found in clinical text and tissue microarchitecture. To this end, we propose PathMoE, an interpretable multimodal framework that integrates H\&E slides, pathology reports, and nuclei-level cell graphs via an interaction-aware mixture-of-experts architecture built on state-of-the-art foundation models for each modality. By training specialized experts to capture modality uniqueness, redundancy, and synergy, PathMoE employs an input-dependent gating mechanism that dynamically weights these interactions, providing sample-level interpretability. We evaluate our framework on two dataset-specific classification tasks on an internal pediatric brain tumor dataset (PBT) and external TCGA datasets. PathMoE improves macro-F1 from 0.762 to 0.799 (+0.037) on PBT when integrating WSI, text, and graph modalities; on TCGA, augmenting WSI with graph knowledge improves macro-F1 from 0.668 to 0.709 (+0.041). These results demonstrate significant performance gains over state-of-the-art image-only baselines while revealing the specific modality interactions driving individual predictions. This interpretability is particularly critical for rare tumor subtypes, where transparent model reasoning is essential for clinical trust and diagnostic validation.

Large language models (LLMs) have achieved expert-level performance on standardized examinations, yet multiple-choice accuracy poorly reflects real-world clinical utility and safety. As patients and clinicians increasingly use LLMs for guidance on complex conditions such as pancreatic cancer, evaluation must extend beyond general medical knowledge. Existing frameworks, such as HealthBench, rely on simulated queries and lack disease-specific depth. Moreover, high rubric-based scores do not ensure factual correctness, underscoring the need to assess hallucinations. We developed a human-in-the-loop pipeline to create expert rubrics for de-identified patient questions from the Pancreatic Cancer Action Network (PanCAN). The resulting benchmark, PanCanBench, includes 3,130 question-specific criteria across 282 authentic patient questions. We evaluated 22 proprietary and open-source LLMs using an LLM-as-a-judge framework, measuring clinical completeness, factual accuracy, and web-search integration. Models showed substantial variation in rubric-based completeness, with scores ranging from 46.5% to 82.3%. Factual errors were common, with hallucination rates (the percentages of responses containing at least one factual error) ranging from 6.0% for Gemini-2.5 Pro and GPT-4o to 53.8% for Llama-3.1-8B. Importantly, newer reasoning-optimized models did not consistently improve factuality: although o3 achieved the highest rubric score, it produced inaccuracies more frequently than other GPT-family models. Web-search integration did not inherently guarantee better responses. The average score changed from 66.8% to 63.9% for Gemini-2.5 Pro and from 73.8% to 72.8% for GPT-5 when web search was enabled. Synthetic AI-generated rubrics inflated absolute scores by 17.9 points on average while generally maintaining similar relative ranking.

Breast cancer is the most frequently diagnosed malignancy among women worldwide and a leading cause of cancer-related mortality. Dynamic contrast-enhanced magnetic resonance imaging plays a central role in tumor characterization and treatment monitoring, particularly in patients receiving neoadjuvant chemotherapy. However, existing artificial intelligence models for breast magnetic resonance imaging are often developed using single-center data and evaluated using aggregate performance metrics, limiting their generalizability and obscuring potential performance disparities across demographic subgroups. The MAMA-MIA Challenge was designed to address these limitations by introducing a large-scale benchmark that jointly evaluates primary tumor segmentation and prediction of pathologic complete response using pre-treatment magnetic resonance imaging only. The training cohort comprised 1,506 patients from multiple institutions in the United States, while evaluation was conducted on an external test set of 574 patients from three independent European centers to assess cross-continental and cross-institutional generalization. A unified scoring framework combined predictive performance with subgroup consistency across age, menopausal status, and breast density. Twenty-six international teams participated in the final evaluation phase. Results demonstrate substantial performance variability under external testing and reveal trade-offs between overall accuracy and subgroup fairness. The challenge provides standardized datasets, evaluation protocols, and public resources to promote the development of robust and equitable artificial intelligence systems for breast cancer imaging.

Precision oncology is currently limited by the small-N, large-P paradox, where high-dimensional genomic data is abundant, but high-quality drug response samples are often sparse. While deep learning models achieve high predictive accuracy, they remain black boxes that fail to provide the causal mechanisms required for clinical decision-making. We present a Neuro-Symbolic Agentic Framework that bridges this gap by integrating a quantitative machine learning World Model with an LLM-based agentic reasoning layer. Our system utilises a forensic data pipeline built on the Sanger GDSC dataset (N=83), achieving a robust predictive correlation (r=0.504) and a significant performance gain through the explicit modelling of clinical context, specifically Microsatellite Instability (MSI) status. We introduce the concept of Inverse Reasoning, where the agentic layer performs in silico CRISPR perturbations to predict how specific genomic edits, such as APC or TP53 repair, alter drug sensitivity. By distinguishing between therapeutic opportunity and contextual resistance, and validating these findings against human clinical data (p=0.023), our framework provides a transparent, biologically grounded path towards explainable AI in cancer research.

Large Language Models (LLMs) are increasingly used for medical entity extraction, yet their confidence scores are often miscalibrated, limiting safe deployment in clinical settings. We present a conformal prediction framework that provides finite-sample coverage guarantees for LLM-based extraction across two clinical domains. First, we extract structured entities from 1,000 FDA drug labels across eight sections using GPT-4.1, verified via FactScore-based atomic statement evaluation (97.7\% accuracy over 128,906 entities). Second, we extract radiological entities from MIMIC-CXR reports using the RadGraph schema with GPT-4.1 and Llama-4-Maverick, evaluated against physician annotations (entity F1: 0.81 to 0.84). Our central finding is that miscalibration direction reverses across domains: on well-structured FDA labels, models are underconfident, requiring modest conformal thresholds ($τ\approx 0.06$), while on free-text radiology reports, models are overconfident, demanding strict thresholds ($τ$ up to 0.99). Despite this heterogeneity, conformal prediction achieves target coverage ($\geq 90\%$) in both settings with manageable rejection rates (9--13\%). These results demonstrate that calibration is not a global model property but depends on document structure, extraction category, and model architecture, motivating domain-specific conformal calibration for safe clinical deployment.

Precision medicine promises to transform health care by offering individualised treatments that dramatically improve clinical outcomes. A necessary prerequisite is to identify subgroups of patients who respond differently to different therapies. Current approaches are limited to static measures of treatment success, neglecting the repeated measures found in most clinical trials. Our approach combines the concept of partly conditional modelling with treatment effect estimation based on the Virtual Twins method. The resulting time-specific responses to treatment are characterised using survLIME, an extension of Local Interpretable Model-agnostic Explanations (LIME) to survival data. Performance was evaluated using synthetic data and applied to clinical trials examining the effectiveness of panitumumab to treat metastatic colorectal cancer. An area under the receiver operating characteristic curve (AUC) of 0.77 for identifying fixed responders was achieved in a 1000 patient simulation. When considering dynamic responders, partly conditional modelling increased the AUC from 0.597 to 0.685. Applying the approach to colorectal cancer trials found genetic mutations, sites of metastasis, and ethnicity as important factors for response to treatment. Our approach can accommodate a dynamic response to treatment while potentially providing better performance than existing methods in instances of a fixed response to treatment. When applied to clinical data we attain results consistent with the literature.

Whole-slide image analysis is essential for diagnostic tasks in pathology, yet existing deep learning methods primarily rely on flat classification, ignoring hierarchical relationships among class labels. In this study, we propose HiClass, a hierarchical classification framework for improved histopathology image analysis, that enhances both coarse-grained and fine-grained WSI classification. Built based upon a multiple instance learning approach, HiClass extends it by introducing bidirectional feature integration that facilitates information exchange between coarse-grained and fine-grained feature representations, effectively learning hierarchical features. Moreover, we introduce tailored loss functions, including hierarchical consistency loss, intra- and inter-class distance loss, and group-wise cross-entropy loss, to further optimize hierarchical learning. We assess the performance of HiClass on a gastric biopsy dataset with 4 coarse-grained and 14 fine-grained classes, achieving superior classification performance for both coarse-grained classification and fine-grained classification. These results demonstrate the effectiveness of HiClass in improving WSI classification by capturing coarse-grained and fine-grained histopathological characteristics.